Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Raz

Showing results (141-150 of 146) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 146 results.
Diabetes, Obesity & Metabolism|October 8, 2015
Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trialL A Leiter, H Teoh, O Mosenzon, et al.
Diabetes, Obesity & Metabolism|February 7, 2015
Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 studyG Leibowitz, A Cahn, D L Bhatt, et al.
Cardiovascular Diabetology|February 12, 2016
LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trialL Masmiquel, L A Leiter, J Vidal, et al.
Diabetes/Metabolism Research and Reviews|April 9, 2013
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trialO Mosenzon, I Raz, B M Scirica, et al.
Heredity|June 3, 2005
Evidence for a major gene affecting the transition from normoglycaemia to hyperglycaemia in Psammomys obesusJ Hillel, D Gefel, R Kalman, et al.
Circulation|October 14, 2015
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized TrialB M Scirica, E Braunwald, I Raz, et al.
Pageof 15

Showing results (141-150 of 146) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 146 results.
Diabetes, Obesity & Metabolism|October 8, 2015
Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trialL A Leiter, H Teoh, O Mosenzon, et al.
Diabetes, Obesity & Metabolism|February 7, 2015
Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 studyG Leibowitz, A Cahn, D L Bhatt, et al.
Cardiovascular Diabetology|February 12, 2016
LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trialL Masmiquel, L A Leiter, J Vidal, et al.
Diabetes/Metabolism Research and Reviews|April 9, 2013
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trialO Mosenzon, I Raz, B M Scirica, et al.
Heredity|June 3, 2005
Evidence for a major gene affecting the transition from normoglycaemia to hyperglycaemia in Psammomys obesusJ Hillel, D Gefel, R Kalman, et al.
Circulation|October 14, 2015
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized TrialB M Scirica, E Braunwald, I Raz, et al.
Pageof 15